Notes :
1. The above unaudited results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 22nd January 2005.

2. The figures for the nine months, the current quarter and the year ended 31st March 2004 reflect the results of the amalgamated company. The figures in the corresponding quarter / nine months in the previous year pertain only to Matrix Laboratories Limited stand alone and to that extent is not comparable. Figures of the earlier periods, have been regrouped to conform to those of the current quarter.

3. The members have approved in their meeting held on 16th December 2004, the stock split from Rs.10 per share to Rs.2 per share and the bonus issue at the rate of 1:1. This has been given effect to in the basic and diluted EPS shown above.

4. The equity capital shown above is pre bonus and split. Post bonus and split, the equity share capital will be Rs.299.48 million (fully paid up Rs.2 each).

5. Provision for tax has been estimated on prorata basis after considering various tax deductions available for the year ending 31st March, 2005.

6. The activities of the Company relate to only one segment i.e. Pharmaceuticals.

7. The company has entered into an agreement on 19th January 2005 with Sigma Laboratories Limited to purchase a Finished Dosage Form manufacturing facility near Nasik.

8. Summary of Investor Complaints :